James Moy to Middle Aged
This is a "connection" page, showing publications James Moy has written about Middle Aged.
Connection Strength
0.281
-
SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine. JAMA Netw Open. 2021 08 02; 4(8):e2119741.
Score: 0.073
-
Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. Eur J Pharm Sci. 2018 Jun 15; 118:80-86.
Score: 0.058
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.
Score: 0.056
-
COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions. mBio. 2021 04 20; 12(2).
Score: 0.018
-
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. N Engl J Med. 2019 05 23; 380(21):2009-2019.
Score: 0.016
-
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 10; 10(14):1193-1202.
Score: 0.015
-
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex? 10% Versus Gammaplex? 5% in Subjects with Primary Immunodeficiency. J Clin Immunol. 2017 Apr; 37(3):301-310.
Score: 0.014
-
Race is associated with differences in airway inflammation in patients with asthma. J Allergy Clin Immunol. 2017 Jul; 140(1):257-265.e11.
Score: 0.013
-
Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA. 2014 May; 311(20):2083-91.
Score: 0.011
-
Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010 Mar; 30(2):321-9.
Score: 0.008